Why GameStop, AmeriGas Partners, and Intercept Pharmaceuticals Tumbled Today

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

Today, the stock market mostly recovered from its poor performance yesterday, with solid retail-sales data and good results on the earnings front from major U.S. banks paving the way for substantial gains of more than 1% for the major broad-market benchmarks. But even amid the cheerful atmosphere, GameStop (NYSE: GME  ) , AmeriGas Partners (NYSE: APU  ) , and Intercept Pharmaceuticals (NASDAQ: ICPT  ) all found themselves on the losing side of the ledger, with substantial share-price declines on the day.

GameStop plunged 20% after the video game retailer said that its holiday-quarter results couldn't live up to high expectations from investors. Gains in U.S. same-store sales of 7.1% and an even more impressive 17.4% jump in international comps helped revenue climb 9.3%, but sales of new software fell by 22.5%. GameStop also gave negative guidance for the quarter, marking down its earnings range by 6% to 9%. Moreover, with Sony (NYSE: SNE  ) offering its own digital distribution alternative recently, GameStop will increasingly have to deal with challenges to its business model even as it suffers natural decay now that new consoles from game-makers have come and gone.

AmeriGas Partners fell 5% after the company priced an offering of 8 million partnership units more than 4% below yesterday's closing price for the units. The master limited partnership, which focuses on the propane distribution industry, sold the units on behalf of an affiliate of Energy Transfer Partners (NYSE: ETP  ) , which had owned 24% of AmeriGas prior to the offering and will own between 14% and 15% following it. The deal represented an exit strategy as part of AmeriGas's acquisition of Energy Transfer Partners' propane business in early 2012.

Intercept Pharmaceuticals dropped for a second straight day, losing 30% as the company said that it might need to enlist the aid of a larger drug-developer in order to maximize the potential success of its liver-disease treatment prospect. At this point, with so far to go before the drug can get approved, let alone marketed, such speculation is only natural -- even if it does lead to wild swings in the stock. For now, though, volatility has become commonplace in the biotech and pharma sector, especially among small development-stage companies with high-profile prospects with promising but uncertain futures.

Find stocks you can rely on
The ideal stock is one you can hold onto for as long as you want. But how can you find great prospects? Our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2795390, ~/Articles/ArticleHandler.aspx, 8/30/2015 8:15:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:01 PM
APU $45.07 Up +0.74 +1.67%
AmeriGas Partners,… CAPS Rating: *****
ETP $49.56 Up +0.95 +1.95%
Energy Transfer Pa… CAPS Rating: *****
GME $42.49 Down -3.71 -8.03%
GameStop CAPS Rating: *
ICPT $188.95 Down -0.39 -0.21%
Intercept Pharmace… CAPS Rating: **
SNE $25.87 Up +0.01 +0.04%
Sony Corp (ADR) CAPS Rating: **